JULIE LOPES: Open Payments
NPI 1821358979 · TUSTIN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$547 in 24 payments from 9 companies in 2025. Trend: 2023 $205 · 2024 $213 · 2025 $547
Food & beverage: $547
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $143 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $114 |
| UCB, Inc. | 1 | $36 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Dexcom, Inc. | 1 | $36 |
| Amgen Inc. | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $17 |
Products named: CAPLYTA, REXULTI, Kerendia, Briviact, Dexcom G6 Transmitter, Repatha, TRELEGY ELLIPTA, JARDIANCE.
Industry payments across CA — which companies pay providers there.
